European Urology Oncology Nationwide Patterns of Care for Stage II Nonseminomatous Germ Cell Tumor of the Testicle  Rashed Ghandour, Caleb Ashbrook, Yuval Freifeld, Nirmish Singla, Jose M. El-Asmar, Yair Lotan, Vitaly Margulis, Scott Eggener, Solomon Woldu, Aditya Bagrodia  European Urology Oncology  DOI: 10.1016/j.euo.2019.06.007 Copyright © 2019 European Association of Urology Terms and Conditions

Fig. 1 A CONSORT flow diagram representing the stepwise exclusion of testicular germ cell tumor patients from the NCDB, reaching the final inclusion of stage II NSGCT patients available for analysis. AJCC=American Joint Committee on Cancer; NCDB=National Cancer Database; NOS=not otherwise specified; NSGCT=nonseminomatous germ cell tumor. European Urology Oncology DOI: (10.1016/j.euo.2019.06.007) Copyright © 2019 European Association of Urology Terms and Conditions

Fig. 2 Bar diagram of the nationwide utilization of RPLND from 2004 to 2014. Graphs represent (A) the primary treatment modality: RPLND versus chemotherapy, and (B) RPLND following chemotherapy (PC-RPLND) versus chemotherapy alone. The X axis represents the year of diagnosis and the Y axis represents the percentage of cases. NSGCT=nonseminomatous germ cell tumor; PC-RPLND=postchemotherapy RPLND; RPLND=retroperitoneal lymph node dissection. European Urology Oncology DOI: (10.1016/j.euo.2019.06.007) Copyright © 2019 European Association of Urology Terms and Conditions